IP Verse

Therapeutic And Diagnostic Target For Cancer Comprising Dll3 Binding Reagents - EP2956483

The patent EP2956483 was granted to Boehringer Ingelheim on May 27, 2020. The application was originally filed on Feb 12, 2014 under application number EP14705561A. The patent is currently recorded with a legal status of "Revoked".

EP2956483

BOEHRINGER INGELHEIM
Application Number
EP14705561A
Filing Date
Feb 12, 2014
Status
Revoked
Sep 9, 2022
Grant Date
May 27, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CHUGAI SEIYAKU KABUSHIKI KAISHAFeb 26, 2021LAHRTZADMISSIBLE
DR H ULRICH DORRIESFeb 26, 2021DORRIESADMISSIBLE
DR H ULRICH DORRIESFeb 26, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE
JAMES POOLEDec 23, 2020CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTEP2530091
INTERNATIONAL-SEARCH-REPORTWO2007111733
INTERNATIONAL-SEARCH-REPORTWO2013126746
OPPOSITIONEP2530091
OPPOSITIONWO2004106380
OPPOSITIONWO2007080597
OPPOSITIONWO2008119567
OPPOSITIONWO2010005567
OPPOSITIONWO2011033105
OPPOSITIONWO2011093097
OPPOSITIONWO2012162067
OPPOSITIONWO2013026837
OPPOSITIONWO2013126746

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- KROESEN ET AL, "Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.", CANCER IMMUNOLOGY, IMMUNOTHERAPY, (19970101), vol. 45, no. 3-4, ISSN 0340-7004, pages 203 - 206, XP055110107 [Y] 1,12-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MARTIN SEBASTIAN ET AL, "Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM anti-CD3): a phase I study", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20070405), vol. 56, no. 10, doi:10.1007/S00262-007-0310-7, ISSN 1432-0851, pages 1637 - 1644, XP019539101 [Y] 1,12-15 * the whole document *
INTERNATIONAL-SEARCH-REPORT- KENTARO MAEMURA, "Delta-likeï¿ 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma", INTERNATIONAL JOURNAL OF ONCOLOGY, (20130117), vol. 42, doi:10.3892/ijo.2013.1778, ISSN 1019-6439, pages 817 - 822, XP055109598 [X] 16-21 * page 817, column l, paragraph 2 - column r, paragraph 2 * * paragraph [results] *
OPPOSITION- THAKUR A et al., "Cancer therapy with bispecific antibodies: Clinical ex- perience", Curr Opin Mol Ther, (20100600), vol. 12, no. 3, pages 340 - 349, XP009145639-
OPPOSITION- Thakur Archana; Lum Lawrence G, "Cancer therapy with bispecific antibodies: Clinical experience.", Current opinion in molecular therapeutics, Thomson Reuters (scietific) Ltd., (20100601), vol. 12, no. 3, ISSN 2040-3445, pages 340 - 349, XP009145639-
OPPOSITION- KROESEN B.J. et al., "Approaches to lung cancer treatment using the CD 3 x EGP-2-directed bispecific monoclonal antibody BIS-1", Cancer Immunol Im- munother, (19971100), vol. 45, no. 3-4, doi:10.1007/s002620050433, pages 203 - 206, XP055110107
OPPOSITION- SEBASTIAN M. et al., "Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti- CD 3): a phase I study", ; Cancer Immunol Immunother, (20070000), vol. 56, doi:10.1007/s00262-007-0310-7, pages 1637 - 1644, XP019539101
OPPOSITION- Kuicheon Choi et al, "Distinct Biological Roles for the Notch Ligands Jagged-1 and Jagged-2", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, (20090626), vol. 284, no. 26, doi:10.1074/jbc.M109.003111, ISSN 0021-9258, pages 17766 - 17774, XP055549320
OPPOSITION- KONTERMANN ROLAND E, "Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica, Nature Publishing Group, GB, GB, (20050101), vol. 26, no. 1, doi:10.1111/j.1745-7254.2005.00008.x, ISSN 1671-4083, pages 1 - 9, XP002426874
OPPOSITION- Reusch Ursula, Sundaram Magesh, Davol Pamela A., Olson Sarah D., Davis James B., Demel Kurt, Nissim Julie, Rathore Ritesh, Liu Paul Y., Lum Lawrence G., "Anti-CD 3 x Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Can- cers In vitro and in an Animal Model ; DOI: 10.1158/1078-0432.CCR-05-1855", 5Department of Medicine, Boston University, Boston, Massachusetts, (20060100), pages 183 - 190, XP003017842
OPPOSITION- Fuhrmann Stacy R., Amann Maria, Mulgrew Kathy, Lorenczewski Grit, Baffa Raffaele, Wolf Andreas, Oberst Michael, Rattel Benno, Lutterbuese Petra, Baeuerle Patrick, Jallal Bahija, Trail Pamela, Richman Laura, Coats Steven, Hammond Scott A., "Abstract 5625: In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas", Annual Meeting of AACR, (20100400), vol. 70, no. 8, pages 1 - 4, XP055978778
OPPOSITION- Baeuerle P A; Reinhardt C; Kufer P, "Bite: a new class of antibodies that recruit T-cells", Drugs of the Future, (20080200), vol. 33, no. 2, pages 137 - 147, XP002667644

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents